Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

E. Alba1*, L. Calvo2, J. Albanell3, J. R. De la Haba4, A. Arcusa Lanza5, J. I. Chacon6, P. SanchezRovira7, A. Plazaola8, J. A. Lopez Garcia-Asenjo9, B. Bermejo10, E. Carrasco11, & A. Lluch10 on behalf of GEICAM Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga; Department of Medical Oncology, C H U Juan Canalejo, A Coruna; Department of Medical Oncology, H del Mar, Barcelona; Department of Medical Oncology, Hospital Reina Sofia, Cordoba; Department of Medical Oncology, Consorci Sanitari de Terrassa, Barcelona; Department of Medical Oncology, H Virgen de la Salud, Toledo; Department of Medical Oncology, C H de Jaen, Jaen; Department of Medical Oncology, Onkologikoa, Donostia; Department of Medical Oncology, H C U San Carlos, Madrid; Department of Medical Oncology, Hospital Clinico Universitario, Valencia; GEICAM, Madrid, Spain